Investigational drug · Phase 2
MK-2010
Also called: LM-299
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Solid Tumors, Malignant Neoplasm, Malignant Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
3
Any phase or sponsor naming "MK-2010"
First trial start
2024
Oct 9, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MK-2010", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Solid Tumors
- Malignant Neoplasm
- Malignant Tumors
- Malignant Neoplam
- Ovarian Cancer Recurrent
Approved drugs for the same conditions: Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "MK-2010" as an intervention, largest first.
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT06843447 · 605 participants (planned) · Start Apr 15, 2025 · Primary completion Mar 27, 2029
Drug: Raludotatug Deruxtecan; Carboplatin and 7 more · For: Ovarian Cancer Recurrent
Sites: New Haven, Connecticut; Louisville, Kentucky; Shreveport, Louisiana · 42 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07793942 · 480 participants (planned) · Start Oct 21, 2026 · Primary completion Sep 26, 2028
Drug: MK-2010; Pembrolizumab and 11 more · For: Malignant Neoplam; Advanced Solid Tumors
Sites: Belleville, New Jersey; East Brunswick, New Jersey; Maumee, Ohio · 7 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07785609 · 200 participants (planned) · Start Oct 7, 2026 · Primary completion Sep 30, 2031
Drug: MK-2010; Sacituzumab tirumotecan and 6 more · For: Advanced Solid Tumors; Malignant Neoplasm
Sites: San Antonio, Texas; Hong Kong, Hong Kong; Bellinzona, Switzerland · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Advanced Solid Tumors
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- AdabelimumabSHR-A2102, SHR2554Phase 320 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Advanced Solid Tumors, Prostate Cancer, Advanced Urothelial Carcinoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- SYS6010Phase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.